]>
IRCT20220813055675N1 IRCT 2022-08-16 Artesh University of Medical Sciences Effects of Ticagrelor on the Clinical consequences of Angioplasty in Myocardial Infarction and Covid-19.d Evaluation of the Effects of Ticagrelor on the Prognosis of Percutaneous Coronary Interventions in Patients with Covid-19 and Comparing it with Clopidogrel 2022-08-20 anticipated 200 Complete https://irct.ir/trial/65269 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, simple randomization method is used by Excel software, and by Random function in this software. The randomization unit in this method will be individual. Patients are divided into two groups: Ticagrelor and Clopidogrel, Blinding description: In this study, the researcher, who is also responsible for the follow-up of patients and the evaluation of the expected outcomes, and finally analyzes the data with the cooperation of statisticians, will be unaware of the type of medicine prescribed for the groups throughout the study. The desired drugs will be prescribed to the patients by the residents, or doctors who coordinate with the research team in the emergency room. 3 Myocardial Infarction. Intervention 1: Intervention group: Ticagrelor drug ("Brilavus" from ABIDI Company) is prescribed orally at the loading dose of 180 mg at the beginning of the patient's visit and before the start of angioplasty, then will be given at the dose of 90 mg every 12 hours as a daily dose. Other prescription drugs are similar to the control group and are performed according to the guidelines. Intervention 2: Control group: Clopidogrel drug ("Plavix" from Sanofi Company) is prescribed orally at the dose of 600 mg at the beginning of the patient's visit and before the start of angioplasty, then will be given at the dose of 75 mg every 24 hours as a daily dose. Other prescription drugs are similar to the intervention group and are performed according to the guidelines. Yes - There is a plan to make this available What will be shared: All collected data can be published. When: Access starts 3 months after the results are published. To whom: All people. Conditions: Any type of data and analysis is accessible. For this purpose, please call 09125752404. Where to obtain: Dr Reza Arefi Zadeh, 501 AJA hospital How to obtain: It is necessary to go to 501 Aja Hospital, cardiology department, or call 09125752404. E-mail: saeedtofighi69@gmail.com is also available for respected clients. Comments:
public Reza Arefi Zade
Etemad Zadeh St., West Fatemi Ave., 501 Aja Hospital
Tehran Iran (Islamic Republic of) 1411718546 +98 21 8609 6350 arefizadehreza@yahoo.com Artesh University of Medical Sciences scientific Saeed Tofighi
No. 30, Parcham St, Tohid Ave.
Tehran Iran (Islamic Republic of) 1457874993 +98 31 5544 8236 saeedtofighi69@gmail.com Artesh University of Medical Sciences Iran (Islamic Republic of) Patients over 18 years of age who present with acute myocardial infarction. Candidates for emergent coronary angioplasty ( Percutaneous coronary intervention ) Less than 24 hours have passed since the onset of chest pain symptoms. are infected with the concomitant covid-19 disease (proved by CT Scan or PCR). 18 years no limit Both Lack of patient consent to perform coronary interventions or enter the study Chronic and necessary use of any anti-coagulant drug by the patient severe renal failure (GFR less than 30) Severe heart failure (EF less than 30%) Age under 18 years old Pregnancy or suspected pregnancy History of intracranial or intraspinal bleeding Administration of any intravenous antiviral drug in the same admision Severe liver failure Past history of any malignancy or chemotherapy regimen I21 ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction Treatment - Drugs Treatment - Drugs Intervention group: Ticagrelor drug ("Brilavus" from ABIDI Company) is prescribed orally at the loading dose of 180 mg at the beginning of the patient's visit and before the start of angioplasty, then will be given at the dose of 90 mg every 12 hours as a daily dose. Other prescription drugs are similar to the control group and are performed according to the guidelines. Control group: Clopidogrel drug ("Plavix" from Sanofi Company) is prescribed orally at the dose of 600 mg at the beginning of the patient's visit and before the start of angioplasty, then will be given at the dose of 75 mg every 24 hours as a daily dose. Other prescription drugs are similar to the intervention group and are performed according to the guidelines. Cardiovascular Death. Timepoint: During the index admission, and after 1 month from hospital discharge. Method of measurement: Admission file and follow-up data. Stent Thrombosis. Timepoint: During index admission and 1 month after discharge. Method of measurement: Coronary Angiography. Myocardial Infarction. Timepoint: During index admission and 1 month after discharge. Method of measurement: Troponin measurement and Electrocardiography. Arterial O2 saturation. Timepoint: During the index admission. Method of measurement: Pulse-Oxymetry. Artesh University of Medical Sciences Approved 2021-12-11 Ethics committee of AJA University of Medical Sciences Etemad Zade St., West Fatemi Ave. Tehran Tehran Iran (Islamic Republic of)